33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Results from phase 3 study of (89)Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON)
    Meeting Abstract

    Shuch, B. M.; Pantuck, A. J.; Bernhard, J. C.; Morris, M. A.; Master, V. A.; Scott, A. M.; Van Praet, C.; Bailly, C.; Aksoy, T.; Merkx, R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Bryce, A. H.; Karp, D. D.; Tagawa, S. T.; Nordquist, L. T.; Rathkopf, D. E.; Adra, N.; Dorff, T. B.; Baeck, J.; O'Donnell, J. F.; Ames, T. D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial
    Meeting Abstract

    Necchi, A.; Roumiguié, M.; Esen, A. A.; Lebret, T.; De Wit, R.; Shore, N. D.; Bajorin, D. F.; Krieger, L. E. M.; Kandori, S.; Uchio, E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical and immunogenomic outcomes of consolidative cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint blockade
    Meeting Abstract

    Reese, S. W.; Jiang, H.; Kuo, F.; Wu, C. Y.; Vuong, L.; Mascareno, E.; Oparanozie, A.; Motzer, R. J.; Voss, M. H.; Reznik, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Extended follow-up results from the CheckMate 274 trial
    Meeting Abstract

    Galsky, M. D.; Witjes, A. A.; Gschwend, J. E.; Schenker, M.; Valderrama, B. P.; Tomita, Y.; Bamias, A.; Lebret, T.; Shariat, S. F.; Park, S. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk
    Meeting Abstract

    Powles, T.; Motzer, R. J.; Albiges, L.; Suárez, C.; Schutz, F. A. B.; Heng, D. Y. C.; Chevreau, C.; Kanesvaran, R.; Gurney, H.; Wang, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Shah, N. J.; Campbell, M. T.; Mao, S. S.; Ornstein, M. C.; Haas, N. B.; Gao, X.; Hammers, H. J.; Keshava-Prasad, H.; Yan, H.; Esquibel, V.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • C-reactive protein (CRP) as a predictive marker for outcomes with avelumab + axitinib (A + Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101
    Meeting Abstract

    Tomita, Y.; Motzer, R. J.; Choueiri, T. K.; Rini, B. I.; Uemura, H.; Oya, M.; Albiges, L.; Fujii, Y.; Umeyama, Y.; Huang, B; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save